252 related articles for article (PubMed ID: 38973)
21. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
Bennett JP; Wooten GF
Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
[TBL] [Abstract][Full Text] [Related]
22. Alterations in dopamine receptors: effect of lesion and haloperidol treatment.
Goldstein M; Lew JY; Asano T; Ueta K
Commun Psychopharmacol; 1980; 4(1):21-5. PubMed ID: 6105037
[No Abstract] [Full Text] [Related]
23. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
Bhargava HN
Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
[TBL] [Abstract][Full Text] [Related]
24. Binding of [3H]apomorphine to striatal membranes prepared from rat brain after 6-hydroxydopamine and kainic acid lesions.
Fujita N; Saito K; Iwatsubo K; Hirata A; Noguchi Y; Yoshida H
Brain Res; 1980 May; 190(2):593-6. PubMed ID: 7370810
[No Abstract] [Full Text] [Related]
25. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--II. Differential localization of dopamine and cholecystokinin receptors.
Beresford IJ; Davenport AP; Sirinathsinghji DJ; Hall MD; Hill RG; Hughes J
Neuroscience; 1988 Oct; 27(1):129-43. PubMed ID: 3264392
[TBL] [Abstract][Full Text] [Related]
26. Changes of the striatal 3H-spiperone binding 3-6 weeks after nigrostriatal denervation and after two years.
Guerin B; Silice C; Mouchet P; Feuerstein C; Demenge P
Life Sci; 1985 Sep; 37(10):953-61. PubMed ID: 3162072
[TBL] [Abstract][Full Text] [Related]
27. Effect of timiperone on 3H-spiroperidol binding to rat striatal dopamine receptors.
Tachizawa H; Sudo K; Sano M
Eur J Pharmacol; 1979 Nov; 59(3-4):245-51. PubMed ID: 43256
[TBL] [Abstract][Full Text] [Related]
28. Reduction of 3H-spiroperidol binding in rat striatum and frontal cortex by chronic amphetamine: dose response, time course and role of sustained dopamine release.
Nielsen EB; Nielsen M; Braestrup C
Psychopharmacology (Berl); 1983; 81(1):81-5. PubMed ID: 6415736
[TBL] [Abstract][Full Text] [Related]
29. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites.
Coupet J; Rauh CE
Eur J Pharmacol; 1979 Apr; 55(2):215-8. PubMed ID: 456420
[TBL] [Abstract][Full Text] [Related]
30. Behavioral and biochemical evidence of apomorphine-induced supersensitivity of the striatal dopamine receptors.
Deshaies P; Bédard P; Falardeau P; Di Paolo T
Neuropharmacology; 1984 Oct; 23(10):1219-22. PubMed ID: 6521857
[TBL] [Abstract][Full Text] [Related]
31. Occupation of dopamine receptors by N-n-propylnorapomorphine or spiperone and acetylcholine levels in the rat striatum.
Korf J; Sebens JB; Flentge F; van der Werf JF
J Neurochem; 1985 Jan; 44(1):314-8. PubMed ID: 3964835
[TBL] [Abstract][Full Text] [Related]
32. Guanine nucleotides do not inhibit tritiated dopamine agonist binding to bovine striatal membranes.
Near JA; Mahler HR
Neurochem Res; 1982 Jul; 7(7):831-7. PubMed ID: 7121724
[TBL] [Abstract][Full Text] [Related]
33. Localization of [3H]N-propylnorapomorphine binding in mouse striatum.
Severson JA; Randall PK
Brain Res; 1983 Nov; 279(1-2):295-8. PubMed ID: 6416612
[TBL] [Abstract][Full Text] [Related]
34. Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors.
Köhler C; Ogren SO; Haglund L; Angeby T
Neurosci Lett; 1979 Jun; 13(1):51-6. PubMed ID: 572522
[TBL] [Abstract][Full Text] [Related]
35. Effects of alloxan-induced diabetes on dopaminergic receptors in rat striatum and anterior pituitary.
Serri O; Renier G; Somma M
Horm Res; 1985; 21(2):95-101. PubMed ID: 3979949
[TBL] [Abstract][Full Text] [Related]
36. The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum.
Traub M; Wagner HR; Hassan M; Jackson-Lewis V; Fahn S
Eur J Pharmacol; 1985 Nov; 118(1-2):147-54. PubMed ID: 3936723
[TBL] [Abstract][Full Text] [Related]
37. Dopamine receptor changes in response to prolonged treatment with L-dopa.
Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
[TBL] [Abstract][Full Text] [Related]
38. Dopaminergic component of [3H]spiroperidol binding in the rat anterior cerebral cortex.
Marchais D; Tassin JP; Bockaert J
Brain Res; 1980 Feb; 183(1):235-40. PubMed ID: 7357406
[No Abstract] [Full Text] [Related]
39. Chronic treatment with metoclopramide induces behavioral supersensitivity to apomorphine and enhances specific binding of 3H-spiroperidol to rat striata.
Lautin A; Wazer D; Stanley M; Rotorsen J; Gershon S
Life Sci; 1980 Jul; 27(4):305-16. PubMed ID: 7412477
[No Abstract] [Full Text] [Related]
40. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.
Hefti F; Melamed E; Wurtman RJ
Brain Res; 1980 Aug; 195(1):123-37. PubMed ID: 6105003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
